Truist Financial Lowers Encompass Health (NYSE:EHC) Price Target to $75.00

Encompass Health (NYSE:EHCGet Rating) had its target price lowered by Truist Financial from $85.00 to $75.00 in a report released on Tuesday morning, The Fly reports. Truist Financial currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on EHC. Stephens lowered their target price on Encompass Health from $78.00 to $74.00 and set an overweight rating for the company in a report on Tuesday. Raymond James lowered their target price on Encompass Health from $85.00 to $70.00 in a report on Friday, June 17th. StockNews.com downgraded Encompass Health from a buy rating to a hold rating in a report on Friday, June 10th. TheStreet upgraded Encompass Health from a c+ rating to a b- rating in a report on Tuesday, March 15th. Finally, Royal Bank of Canada decreased their price objective on Encompass Health from $85.00 to $82.00 in a report on Wednesday, June 8th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Encompass Health presently has an average rating of Buy and a consensus target price of $79.56.

EHC opened at $54.72 on Tuesday. The firm has a market cap of $5.46 billion, a P/E ratio of 13.99, a price-to-earnings-growth ratio of 1.80 and a beta of 0.96. Encompass Health has a 52-week low of $53.03 and a 52-week high of $85.75. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.26. The business’s fifty day moving average is $63.87 and its 200-day moving average is $65.26.

Encompass Health (NYSE:EHCGet Rating) last announced its quarterly earnings results on Wednesday, April 27th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Encompass Health had a return on equity of 17.99% and a net margin of 7.51%. The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period last year, the firm posted $1.05 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, research analysts predict that Encompass Health will post 4.09 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 20th. Investors of record on Wednesday, July 13th will be issued a dividend of $0.28 per share. The ex-dividend date is Tuesday, July 12th. This represents a $1.12 annualized dividend and a yield of 2.05%. Encompass Health’s dividend payout ratio (DPR) is currently 28.64%.

In other Encompass Health news, Director Kevin J. O’connor acquired 1,000 shares of the business’s stock in a transaction on Friday, May 6th. The shares were acquired at an average price of $66.48 per share, with a total value of $66,480.00. Following the completion of the transaction, the director now owns 3,436 shares in the company, valued at $228,425.28. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.70% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of EHC. Whittier Trust Co. purchased a new position in Encompass Health in the fourth quarter worth $26,000. Signaturefd LLC lifted its position in shares of Encompass Health by 58.9% during the 4th quarter. Signaturefd LLC now owns 499 shares of the company’s stock valued at $33,000 after buying an additional 185 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Encompass Health during the 1st quarter valued at $33,000. Parallel Advisors LLC lifted its position in shares of Encompass Health by 103.1% during the 4th quarter. Parallel Advisors LLC now owns 532 shares of the company’s stock valued at $35,000 after buying an additional 270 shares during the last quarter. Finally, Worth Asset Management LLC purchased a new position in shares of Encompass Health during the 1st quarter valued at $35,000. 91.70% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Company Profile (Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Featured Articles

The Fly logo

Analyst Recommendations for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.